Results 321 to 330 of about 3,093,388 (334)
Some of the next articles are maybe not open access.
Involvement of interleukin‐21 in the pathophysiology of aplastic anemia
European Journal of Haematology, 2015AbstractObjectiveRecently enhanced T‐helper type 17 (Th17) immune responses and deficient CD4+CD25hiFoxP3+ regulatory T cells (Tregs) have been reported in acquired aplastic anemia (AA). Interleukin‐21 (IL‐21), a CD4+ T‐cell‐derived proinflammatory cytokine, modulates the balance between Th17 cells and Tregs.
Jianfeng Yao +7 more
openaire +2 more sources
Interleukin 21: A Key Player in Lymphocyte Maturation
Critical Reviews in Immunology, 2004The common gamma chain family of cytokine receptors plays a plethora of roles during the early development, activation, and terminal differentiation of the lymphocyte lineages. The most recently identified member of this family, the IL-21R, is expressed to varying degrees on B, T lymphocytes, and natural killer (NK) cells, whereas IL-21, is reportedly ...
Jason Brady +3 more
openaire +3 more sources
Expression, purification and characterization of recombinant interleukin-21
Journal of Immunological Methods, 2010Interleukin-21 (IL-21) is a key regulator of the immune system. However, studies of this cytokine have so far been hampered by the limited availability of recombinant protein preparations. Here we describe a method based on refolding of inclusion bodies expressed in E. coli by rapid dilution.
Helen M. McGuire +7 more
openaire +3 more sources
Interleukin 21 as a target of intervention in autoimmune disease
Annals of the Rheumatic Diseases, 2008Interleukin 21 (IL21) belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine receptor gamma chain (gamma(C)). The IL21R is widely distributed on lympho-haematopoietic cells and IL21 impacts a number of cell types, including CD8+ memory T cells, NK cells and subsets of CD4 ...
Rachel Ettinger +2 more
openaire +3 more sources
Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial.
International journal of clinical pharmacology and therapeutics, 2016OBJECTIVE This first-in-human, randomized, double-blind, placebo-controlled trial assessed the safety of NNC0114-0005, a human recombinant anti interleukin (IL)-21 monoclonal antibody, for the treatment of rheumatoid arthritis (RA).
S. Ignatenko +2 more
semanticscholar +1 more source
Interleukin-21 mRNA expression during virus infections
Cytokine, 2006Interleukin-21 is a cytokine with profound impact on the proliferation and differentiation of activated leukocytes of both the innate and adaptive immune system. In experiments in vitro, antigen activation induces IL-21 production in CD4+ T cells. Where, when, and how the proliferative and activational effects of IL-21 on different leukocytes come into
Holm, Christian +5 more
openaire +5 more sources
Interleukin-21 in T cell-mediated diseases.
Discovery medicine, 2009Interleukin-21 (IL-21), a cytokine produced by activated CD4+ T cells, activated natural killer T cells, and T follicular cells, has been reported to play a crucial role in the tissue-damaging T cell response in various organs, such as gut, skin, pancreas, and joints.
MONTELEONE, GIOVANNI +2 more
openaire +2 more sources
Reactome - a curated knowledgebase of biological pathways, 2017
S Jupe, Birgit H M Meldal
openaire +2 more sources
S Jupe, Birgit H M Meldal
openaire +2 more sources
Interleukin 21 – its potential role in the therapy of B-cell lymphomas
Leukemia and Lymphoma, 2017Shruti Bhatt, K. Sarosiek, I. Lossos
semanticscholar +1 more source